Active Biotech AB

251 articles about Active Biotech AB

• 

  Active Biotech's Laquinimod Fails to Meet Primary Endpoint in Phase II Trial

  12/1/2017

  The primary endpoint of brain atrophy as defined by PBVC from baseline to week 48, was not met after daily oral doses with 0.6 mg laquinimod.

• Annual General Meeting Of Active Biotech

  6/16/2017

• Teva, Active Biotech Suffer Another Setback After Laquinimod Flunks MS Study

  5/8/2017

• Active Biotech, NeoTX Ink $71 Million+ Immuno-Oncology Pact

  10/26/2016

• FDA Takes Back Special Protocol Assessment for Active Biotech's Laquinimod

  9/19/2016

• Teva, Active Biotech Stop Higher Doses of Laquinimod in Two Multiple Sclerosis Trials

  1/4/2016

• Active Biotech's Partner Teva Presents Data On Laquinimod For The Treatment Of Multiple Sclerosis At 31st ECTRIMS Congress

  10/6/2015

• Teva And Active Biotech Announce Completion Of Patient Enrollment In Laquinimod Phase III CONCERTO Trial

  6/25/2015

• Active Biotech Forced to Cut 47 of 56 Staffers After Phase III Prostate Cancer Failure

  6/2/2015

• Teva And Active Biotech AB Announce First Patient Enrolled In Phase II Study Evaluating Laquinimod For Primary Progressive MS

  4/23/2015

• Ipsen, Active Biotech AB Plummet As Prostate Cancer Drug Flunks Late-Stage Trial

  4/17/2015

• Teva Pharmaceutical Industries Limited And Active Biotech AB Announce Expansion Of Laquinimod Clinical Development Program With New Trial In Primary Progressive Multiple Sclerosis And First Patient Screened In Huntington’s Disease Trial

  11/4/2014

• Active Biotech AB Presents Data On Paquinimod At EULAR 2014

  6/11/2014

• Active Biotech AB To Present At Jefferies and Co. 2014 Healthcare Conference

  6/3/2014

• Despite Rejection, Teva Pharmaceutical Industries Limited And Active Biotech AB Remain Committed To The Development Of Multiple Sclerosis Nerventra®

  5/23/2014

• Annual General Meeting Of Active Biotech AB

  5/16/2014

• Active Biotech AB Interim Report January - March 2014

  4/24/2014

• Active Biotech AB - Notice Of Annual General Meeting Of Shareholders

  4/14/2014

• Annual Report 2013 Active Biotech AB

  4/7/2014

• Active Biotech AB Release: Change In The Clinical Development Program For Laquinimod

  2/19/2014